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biliary obstruction remains unclear, and includes the possible per-
formance of magnetic resonance cholangiopancreatography (MRCP)
and endoscopic retrograde cholangiopancreatography (ERCP). Objec-
tives: To complete a cost analysis based on a medical effectiveness
randomized trial comparing an ERCP-ﬁrst approach with an MRCP-
ﬁrst approach in patients with suspected bile duct obstruction.
Methods: The management strategies were based on a medical
effectiveness trial of 257 patients over a 12-month follow-up period.
Direct and indirect costs were included, adopting a societal perspec-
tive. The cost values are expressed in 2012 Canadian dollars. Results:
Total per-patient direct costs were Can$3547 for ERCP-ﬁrst patients
and Can$4013 for MRCP-ﬁrst patients. Corresponding indirect costs
were Can$732 and Can$694, respectively. Causes for differences in
direct costs included a more frequent second procedure and a greateree front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.04.009
un@muhc.mcgill.ca.
ondence to: Alan N. Barkun, Division of Gastroent
edar Avenue, Room D7.346, Montréal, Canada H3mean number of hospital days over the year in patients of the MRCP-
ﬁrst group. In contrast, it is the ERCP-ﬁrst patients whose indirect
costs were greater, principally due to more time away from activities
of daily living. Choosing an ERCP-ﬁrst strategy rather than an MRCP-
ﬁrst strategy saved on average Can$428 per patient over the 12-month
follow-up duration; however, there existed a large amount of overlap
when varying total cost estimates across a sensitivity analysis range
based on observed resources utilization. Conclusions: This cost anal-
ysis suggests only a small difference in total costs, favoring the ERCP-
ﬁrst group, and is principally attributable to procedures and hospital-
izations with little impact from indirect cost measurements.
Keywords: biliary obstruction, costs, ERCP, MRCP.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The optimal management of patients with a moderate likelihood
of biliary obstruction after initial laboratory tests and imaging
with ultrasound remains unclear, especially in the presence of
many noninvasive imaging options, including magnetic reso-
nance cholangiopancreatography (MRCP) and endoscopic retro-
grade cholangiopancreatography (ERCP) [1–3]. In addition to
malignancies such as pancreatic cancer [4], which carry a signiﬁ-
cant burden of illness, most of the societal costs are probably
related to one of the most frequent causes of biliary obstruction in
a general medical practice: common bile duct stones or choledo-
cholithiasis. Indeed, gallstone disease (gallbladder, including 10% of
these patients who carry common bile duct stones [1,3,5–7]) is
responsible for about 1.8 million ambulatory care visits and more
than 700,000 cholecystectomies yearly in the United States [1,8,9].
Gallstone disease is the second most common reason for hospital
admissions (with an estimated cost of US $5.8 billion annually),
although only 15% of the people with gallstones have relatedsymptoms [1,3,5–7]. The initial management strategy needs to
consider the diagnostic yield of these technologies and weigh the
beneﬁts with the small but signiﬁcant complications attributable to
ERCP, which, however, can also provide therapy.
We completed a medical effectiveness randomized trial com-
paring an ERCP-ﬁrst approach with an MRCP-ﬁrst approach in
patients with suspected bile duct obstruction after an initial
clinical evaluation and ultrasound examination, in whom a
further workup was needed to establish a diagnosis. The follow-
ing cost analysis is based on original utilization data collected as
part of the trial.Methods
The Randomized Clinical Source Trial
This cost analysis is based on a recently published randomized
controlled trial (RCT) [10] comparing ERCP with MRCP in theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
erology, The McGill University Health Center, Montreal General
G 1A4.
Table 1 – Unit costs.
Cost item Cost
value*
Source
Visit (gastroenterology) 25 RAMQ [19]
Consultation (gastroenterology) 150 RAMQ [19]
Total cost for an ERCP procedure
(diagnosis) as initial procedure
1449 RAMQ [19];
CIHI [13]
Total cost for an ERCP procedure
(therapeutic) as initial procedure
1539 RAMQ [19];
CIHI [13]
Total cost for an ERCP procedure
(diagnosis) as secondary procedure
1324 RAMQ [19];
CIHI [13]
Total cost for an ERCP procedure
(therapeutic) as secondary
procedure
1414 RAMQ [19];
CIHI [13]
Total cost for an MRCP procedure 1270 RAMQ [19];
CIHI [13]
Hospitalization for pancreatitis 4878 CIHI [13]
Hospitalization for gatrointestinal
hemorrhage
3677 CIHI [13]
Hospitalization for peforation 7001 CIHI [13]
Hospitalization for cholangitis 4224 CIHI [13]
Hospitalization for cholecystectomy 4401 CIHI [13]
Average per diem cost for
hospitalizations due to
complications in suspected biliary
obstruction
911 CIHI [13]
Time lost (1 d)† 127 Statistics
Canada
[21]
Note. Values were rounded to the nearest integer.
CIHI, Canadian Institute for Health Information; ERCP, endoscopic
retrograde cholangiopancreatography; MRCP, magnetic resonance
cholangiopancreatography; RAMQ, Régie de l'Assurance Maladie
du Québec.
* All costs are expressed in 2012 Canadian dollars.
† Blended average cost that could vary according to age and sex
group of the patient.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 6 7 – 7 7 3768management of patients at moderate likelihood of a suspected
biliary obstruction.
The RCT comparing MRCP with ERCP provided information
about the main medical resources of all 257 included patients and
time lost related to the suspected biliary obstruction with its
assessment and management. We calculated the observed direct
costs resulting from the observed medical visits, ERCP and MRCP
procedures, and hospitalizations. Indirect costs were also tabu-
lated on the basis of observed time lost because of the medical
condition.
In the randomized trial, the patients were randomized to an
ERCP-ﬁrst strategy or an MRCP-ﬁrst strategy, stratiﬁed by the
level of obstruction. The primary outcome was the occurrence of
a disease- or procedure-related biliopancreatic adverse event
within the next 12 months. Secondary outcomes were the
number of subsequent biliopancreatic procedures, the duration
of hospitalization, days away from activities of daily living (ADL),
and mortality. In this trial, a strategy of MRCP-ﬁrst decreased the
need for subsequent MRCPs but not complications. The source
RCT was conducted at the McGill University Health Centre and
the Sir Mortimer B. Davis – Jewish General hospital, two tertiary
care centers in Montreal (Canada). All patients older than 18
years with suspected biliary obstruction over a 4-year period were
considered for recruitment if they were referred for a noninvasive
radiological investigation (ultrasound or computed tomography
scan of the abdomen) showing a dilated common bile duct or
directly for an ERCP or MRCP. The patients were openly allocated
to one of the two study groups and followed for 12 months [10]. A
scheduled follow-up visit was planned every 3 months. Only
pertinent durations of hospitalization were measured, as deﬁned
by any hospitalization because of the workup or treatment of the
biliopancreatic condition, or any adverse event thereof as deter-
mined by an ad hoc expert panel.
The trial was recently published [10] and, in brief, 126 patients
were randomized to an ERCP-ﬁrst and 131 to an MRCP-ﬁrst
strategy (both groups exhibiting similar characteristics, age 54 
18 years, 62% women, 39% postcholecystectomy). In follow-up, 18
(14.3%) ERCP-ﬁrst and 25 (19.1%) MRCP-ﬁrst patients experienced
a procedure- or disease-related complication (P ¼ 0.30). A cause of
biliary obstruction was found in 39.7% versus 49.6% of the
patients (P ¼ 0.11). Sixty-six (50%) patients in the MRCP-ﬁrst
group ended up avoiding an ERCP in follow-up. Overall, 20 (7.8%)
patients died during the study period, with no signiﬁcant differ-
ence between the two groups (7.9% for ERCP and 7.7% for MRCP;
P ¼ NS) and no procedure-related mortality.
General Considerations as to the Determination of Costs
We associated a cost to each of the resources used by both
randomized groups of patients as collected in follow-up. Direct
and indirect costs were included. We performed our cost analysis
assuming that all other factors remained the same outside
disease- or procedure-related resources, especially because we
only collected disease-related resource utilization as described
above. In other words, we assumed that there were no differ-
ences in transportation costs, in personal consumption of phar-
maceutical drugs, or in utilization of medical care services other
than for the RCT-related medical conditions in both groups. All
procedures, physician visits, lengths of stay, and disease-related
complications were recorded in the RCT. Enrolled patients also
received a questionnaire quantifying the time spent away from
their usual activities because of the ERCP/MRCP procedure.
A societal perspective was adopted [11,12].
For each strategy (ERCP-ﬁrst and MRCP-ﬁrst), a total direct
average cost per patient was computed according to the study
group, including the costs of the visits, as well as ERCP and MRCP
procedures (initial and additional) with the correspondingphysician fees (consultation costs were included in ERCP/MRCP
procedures), and all days of hospitalization.
We present the mean quantity of individual resource utiliza-
tions by study group (Table 2), the time lost per patient (Table 3),
and calculated the corresponding average direct and indirect
costs at the patient level with lower and upper quartile estimates
(Table 4). All cost results cover a 12-month study horizon
paralleling the RCT study design. The cost values presented in
this analysis are expressed in 2012 Canadian dollars (Can$).
Determination of Direct Costs
Hospitalization Costs
Direct hospitalization costs were derived from the Canadian
Institute for Health Information (CIHI) [13] (Table 1). CIHI is a
Canadian organization that provides national estimates of med-
ical resources on the basis of a relative resource allocation
methodology for estimating a hospital’s inpatient cost. More
precisely, this organization computes a resource intensity weight
per homogeneous case-mix group of diagnoses (CMG) based on
International Classiﬁcation of Diseases, Tenth Revision diagnostic
codes. This resource intensity weight per CMG (that includes all
institutional costs with overhead costs but without physician
fees) is then multiplied by a unique average cost per weighted
case to give a ﬁnal hospitalization cost per CMG. Using the CIHI
estimations, we therefore computed a per diem cost associated
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for our patient population. This computed per diem cost was the
average cost of an adult admission registered for one of ﬁve
selected CMGs—277 (pancreatitis), 254 (gastrointestinal hemor-
rhage), 251 (perforation), 278 (cholecystectomy), and 288 (chol-
angitis)—that represent the most commonly related
complications for the condition of suspected biliary obstruction
with an impact on hospitalizations or costs [14–18]. Patients who
die during the hospitalization are excluded from cost estimates
by the CIHI.
Physician Fees
The physician fees were derived from the single-payer provincial
government, the Régie de l’Assurance Maladie du Québec [19].
Procedural Costs
We also estimated direct costs for MRCP and separate direct costs
for a diagnostic or a therapeutic ERCP, depending on whether
they were an initial or additional ERCP in the patient’s manage-
ment. In each comparison group, the percentages of diagnostic
and therapeutic ERCPs were obtained from results of the source
RCT [10]. These were 67.5% and 32.5% for the diagnostic and
therapeutic initial ERCP procedures, respectively. Corresponding
percentages for subsequent ERCPs were 44.4% and 55.6%. Among
patients randomized to an MRCP-ﬁrst strategy, 16.7% underwent
a subsequent ERCP for sole diagnostic purposes; all others were
therapeutic ERCPs. The total direct costs of each procedure were
tabulated as the sums of the institutional fees and all profes-
sional fees related to the performance of ERCP or MRCP. For initial
ERCP procedures, we assumed that a consultation in gastro-
enterology was required, versus only a visit for subsequent
ERCPs. Estimates of institutional costs for ERCP and MRCP
procedures were derived from the CIHI [13].
Determination of Indirect Costs
According to the human capital approach [11,20], indirect cost as
an opportunity cost was based on the loss of productivity, that is,
the time lost because of the condition of suspected biliary
obstruction. This time was tabulated as the sum of the lengths
of stays due to the hospitalizations, the time required for ERCP/
MRCP initial and follow-up procedures, the time used for the
medical visits, and any time lost in the patient’s ADL. All times
away from ADL were obtained from the trial’s patient question-
naires unless speciﬁed above. The value of a patient’s time was
based on the hourly wages provided by Statistics Canada [21]. For
the time spent away from usual activities, a speciﬁc hourly value
was applied according to the age and sex of the respondents toTable 2 – Medical resources utilization (per patient).
Medical item M
Number of patients
Total number of visits (gastroenterology)
Initial procedure (ERCP and MRCP for each group)
Number of additional procedures (MRCP and ERCP)
Number of all ERCP-MRCP procedures
Total number of days of hospitalization*
Note. Values were rounded to the nearest two decimals.
ERCP, endoscopic retrograde cholangiopancreatography; MRCP, magneti
* Sum of all the days of hospitalization for all patients/number of patient
ERCP-ﬁrst versus 4.6 d for MRCP-ﬁrst. Difference in both formulas arisethe questionnaire. For the length of stay and the time spent to
undergo ERCP and MRCP, a uniform average hourly wage for all
the patients was used. We assumed that a patient spent 1 day to
undergo an ERCP and a half-day for an MRCP or a visit in
gastroenterology. The unit costs are presented in Table 1.Sensitivity Analyses
We performed sensitivity analyses varying the clinically relevant
outcomes across a meaningful range of possibilities (i.e., the
lower and upper quartiles of units used of this resource multi-
plied by the unit resource cost) as informed by the RCT results.Results
Direct Costs
Data for the use of medical resources are presented in Table 2.
Average costs attributable to visits were similar in both groups.
The MRCP-ﬁrst group required a second procedure more often
and exhibited more days of hospitalization than did the ERCP-
ﬁrst group. Table 4 provides the average direct costs per patient
(with lower and upper bounds) generated by the medical resource
utilization presented in Table 2. Procedures and hospitalizations
(representing 99% of all direct costs) are the two resources that
account for most of the Can$428 in additional total costs
attributable to the MRCP-ﬁrst group in comparison with the
ERCP-ﬁrst group.Indirect Costs
Table 3 details the estimation of the time lost by patients because
of their condition. In terms of time lost, all four categories of
indirect costs (visits, procedures, hospitalization, and time away
from ADL) contributed signiﬁcantly to the overall indirect cost
burden. Table 3 demonstrates that it is the ERCP-ﬁrst patients
who lose more time away from ADL. The corresponding cost
values are presented in Table 4, demonstrating that the biggest
difference in indirect costs stems from time away from ADL.
Absolute per-patient cost values are shown in Figure 1. On
average, the management of a patient with suspected biliary
obstruction costs Can$4279 using an ERCP-ﬁrst approach versus
Can$4707 when adopting an MRCP-ﬁrst approach. In other words,
choosing an ERCP-ﬁrst strategy rather than a MRCP-ﬁrst strategy
would save on average Can$428 per patient in follow-up, based
on the data gathered from the source RCT.ean per patient in the
ERCP-ﬁrst group
Mean per patient in the
MRCP-ﬁrst group
126 131
1.7 1.76
1 1
0.29 0.56
1.29 1.56
1.81 2.11
c resonance cholangiopancreatography.
s. The average of the mean duration of stay per patient was 4.1 d for
s because some patients had more than one hospitalization.
Table 3 – Time lost (in days, per patient).
Time category Mean per patient in the ERCP-ﬁrst
group
Mean per patient in the MRCP-ﬁrst
group
Number of patients 126 131
Total time spent for visits in
gastroenterology
0.85 0.88
Total time spent to undergo ERCP or MRCP 1.21 1.03
Total time spent at hospital 1.81 2.11
Total of additional time spent away from
ADL*
1.96 1.55
Note. Values were rounded to the nearest two decimals.
ADL, activities of daily living; ERCP, endoscopic retrograde cholangiopancreatography; MRCP, magnetic resonance cholangiopancreatography.
* Sum of all the days spent away from ADL for all patients/number of patients. The average of the mean duration of stay per patient was 3.4 d
for ERCP-ﬁrst versus 2 d for MRCP-ﬁrst. Difference in both formulas arise because patients had variable numbers of events causing days away
from ADL.
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ERCP and MRCP are among the most commonly performed
procedures to investigate suspected biliary obstruction [1]. There
exists equipoise as to which may be the best approach. This
uncertainty lies in the realization that ERCP carries more risks,
yet also offers the possibility of performing therapy at the same
procedural setting. We recently published the ﬁnal results of an
RCT comparing an ERCP-ﬁrst approach with an MRCP-ﬁrst
approach in patients with suspected lower bile duct obstruction
[10], concluding that an MRCP-ﬁrst strategy decreased the need
for subsequent MRCPs but did not alter a priori–deﬁned bilio-
pancreatic or procedure-related adverse events, which was the
most relevant single clinical outcome and was the primary
outcome of the trial. We now compared the cost information
collected as part of that trial, in the hope of better characterizing
the two strategies.
After quantifying the direct costs of all medical resources
used, we also estimated the indirect costs resulting from time
lost because of the medical condition and its related diagnosis
and treatment, although we did not capture transportation or
caregivers’ time-related costs. Total costs added up to Can$4279
per patient in the ERCP-ﬁrst strategy and Can$4707 per patient in
the MRCP-ﬁrst strategy, for a difference of Can$428.
Although the ERCP-ﬁrst patients lose more time away from
ADL, there is a greater cost attributable to increased procedures
and more days of hospitalizations noted in the MRCP-ﬁrst
patients. It is thus mainly the direct costs that account for the
difference between each strategy over a 12-month period. A
review of upper and lower quartile variations, however, shows
great overlap between per-patient cost estimates in both groups.
Many interpretations are possible. Because the savings represent
about 10% of the total per-patient costs associated with either
approach, the mean difference may be a valid unbiased (albeit
uncertain) estimate, in which case the ERCP-ﬁrst strategy could
be favored as slightly more economically viable. Alternately, the
mean difference of Can$428 in cost could be interpreted as
unimportant given variability in the costs, and the procedures
could be considered equivalent. However, we feel that the most
conservative and likely interpretation (especially in light of the
difference in clinical procedural risks) is that the analysis is
inconclusive because the trial was too small and the uncertainty
over the cost difference resultantly too big.
These ﬁndings were somewhat surprising because the MRCP
diagnostic test is touted to be less invasive than the ERCP
alternative, which bears signiﬁcantly greater risks. This observa-
tion is likely explained by the number of MRCP-ﬁrst patients whosubsequently underwent an ERCP (66 of 131) (probably because of
persistent diagnostic uncertainty resolved by the performance of
the more invasive diagnostic approach), as well as the down-
stream hospitalizations noted in the MRCP-ﬁrst group (this latter
difference may have been related to chance alone because there
are no biological explanations for this ﬁnding). The actual differ-
ence in procedure institutional unit costs between ERCP and
MRCP is minimal (Table 1) [13]. There exist, however, differences
in physician fees for each procedure, especially with regard to the
performance of a therapeutic ERCP in keeping with provincial
reimbursement schedules [19].
A number of methodological and clinical issues are worth
mentioning. The data, particularly the probabilities and efﬁcacy
information, were drawn directly from the RCT ﬁndings. Because
these data are a result of direct clinical observation and not
theoretical assumptions, their clinical relevance is obviously
heightened; indeed the medical resources recorded did not stem
from a retrospective gathering of self-report questionnaires but
rather from actual medical management information as deter-
mined by prospective data collection by research nurses in a
standardized fashion. Although more generalizable because the
study was designed as a medical effectiveness trial, the data may
still be limited in their external validity, especially because the
RCT was carried out only in two hospitals, on three sites; the
selection of patients was also more explicit and systematized
than may be the case in general practice. This randomized trial,
however, is the only such evaluation having been completed in
the literature that attempts to measure the true downstream
clinical impact of an ERCP-ﬁrst strategy versus an MRCP-ﬁrst
strategy in diagnosing and then treating patients with a moder-
ate likelihood of biliary obstruction (stricture or stone). Such
evaluative attempts, in general, are few because the intervention
(diagnostic) may occur far upstream in the clinical pathway of a
given patient, when compared with the ﬁnal clinical outcome. A
recent RCT suggested a lesser complication burden when per-
forming an endoscopic ultrasonography–ﬁrst compared with an
ERCP-ﬁrst approach [22]. Although the approach to patients with
biliary obstruction emphasizes a noninvasive paradigm, the
general principles of the clinical paths adopted in the trial and
the technologies of ERCP and MRCP used then are very much
similar to those used today, both in Canada and in other Western
and Asian countries. Local practices with access to endoscopic
ultrasonography expertise and equipment may alter the choice of
noninvasive imaging, yet in many centers, endoscopic ultra-
sonography resources, such as in our own, are mainly taken up
by indications for malignant diseases, including extrabiliary
organs such as esophagus, stomach, duodenum, rectum,
and lung.
Table 4 – Total direct and indirect costs*.
ERCP-ﬁrst group MRCP-ﬁrst group
Cost center Average cost
per patient
Proportion of total direct/
indirect costs (%)
Lower
bound
Upper
bound
Average cost
per patient
Proportion of total direct/
indirect costs (%)
Lower
bound
Upper
bound
Direct costs
Gastroenterology visits 42 1 25 100 44 1 37 125
Procedure ERCP/MRCP 1856 52 1443 2888 2043 51 1303 2608
Hospitalizations 1648 46 911 4100 1926 48 911 4255
Total direct costs 3547 100 2379 7088 4013 100 2251 6988
Indirect costs
Time spent on
gastroenterology
visits
108 15 63 255 112 16 95 318
Time spent on ERCP/
MRCP procedures
154 21 119 241 131 19 122 170
Time spent at hospital 230 31 100 358 269 39 96 438
Time spent away from
ADL
239 33 0 652 183 26 0 439
Total indirect costs 732 100 282 1506 694 100 313 1365
Total direct and indirect
costs
4279 2661 8594 4707 2564 8353
Note. Values were rounded to the nearest integer. Low and high values are based on the lower (25%) and upper (75%) quartiles.
ADL, activities of daily living; ERCP; endoscopic retrograde cholangiopancreatography; MRCP, magnetic resonance cholangiopancreatography.
* All costs are expressed in 2012 Canadian dollars.
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Fig. 1 – Per-patient costs.
Period of time: 12 months.
ERCP, endoscopic retrograde cholangiopancreatography; MRCP, magnetic resonance cholangiopancreatography; DC, direct
costs; IC, indirect costs.
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warrants discussion. We adopted a societal perspective as rec-
ommended [11,12,23–26]. The unit direct costs were based mainly
on representative national averages. Only a limited number of
physician fees were province-speciﬁc for Quebec [19], and these
latter costs represent just a small part of the total direct costs. We
included all follow-up resources noted by the research nurses,
but here too are once again limited by the information available
from the RCT [10]. The ﬁve diagnoses identiﬁed for the calculation of
the per diem in this analysis (pancreatitis, gastrointestinal hemor-
rhage, perforation, cholecystectomy, and cholangitis) represent the
most common complications encountered, both related to proce-
dures (ERCP) and the natural history of the conditions most
frequently found to be the cause of lower biliary obstruction (gall-
stones with or without choledocholitiasis, and more rarely in a
general practice, pancreatic cancer). The choice of time horizon is
adapted to the clinical context as detailed in the randomized trial
protocol and publication, and was limited by the follow-up in our
RCT. Either a longer follow-up or a longer time horizon could affect
point estimates, although it is unlikely that the general conclusions
would be altered considering the natural history of the clinical
conditions under study [1,27].
The indirect costs are expressed as “productivity losses”
according to the concept of opportunity cost [11,12]. They were
computed following the capital human approach often applied in
health economics, one that is recommended when adopting a
societal perspective, even though this method may lead to over-
estimates and adopts general assumptions [11,25,28,29]. The
methods for estimating indirect costs, however, are still a matter
of debate [11,25,29,30]. Because of possible inequities in the labor
market and other conceptual arguments, some have suggested a
friction cost method instead [31,32]. Unfortunately, this alternate
approach requires a large amount of detailed source infor-
mation, something that is seldom available [25]. Regardless, we
are ultimately interested most in incremental between-groupdifferences from a clinical perspective, unless a systematic bias
would exist favoring one or the other randomization arm, which
is unlikely considering the clinical paths under study and the
time horizon adopted.
The unit indirect costs were issued from general average wage
rates per sex and age group for the time spent away from ADL, and
from average daily wages for the time spent at the hospital (i.e.,
procedures, follow-up, and hospitalizations postprocedure). Hence,
we did not use the real personal earnings of each patient enrolled in
the RCT. We followed the recommendations to present both the
quantity of lost time and the correspondent monetary value using
general rate wages [11,25,29]. Themeasure of time lost was based on
the recorded length of stay in hospital, in addition to the time spent
away from ADL according to the patient, and a standardized
assumed time necessary for a procedure (1 day for ERCP, half-day
for an MRCP) and follow-up visits (half-day). Patients responded to a
questionnaire estimating the time spent away from ADL with
resultant limitations of recall bias and subjectivity. A more precise
approach such as that recommended by Groover [33] that takes into
consideration daily patient notes about each activity, time lost, and
time motion approaches (e.g., to determine exact travel times) is
difﬁcult to apply in routine clinical medical research. The cost
attributable to caregivers was not assessed, but may not be as
applicable in this clinical context of what is most often an acute
relapsing condition over a short time horizon. Intangible costs such
as those attributable to pain or discomfort were not considered.Conclusions
This cost analysis based on the randomized trial comparing the
diagnostic strategies of MRCP-ﬁrst and ERCP-ﬁrst approaches in
patients with suspected biliary obstruction due to bile duct
stones suggests only a small difference in total per-patient costs.
The Can$428 per-patient increment favors the ERCP-ﬁrst
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 6 7 – 7 7 3 773approach, and is principally attributable to procedural and
hospitalization costs with little impact from indirect cost meas-
urements; however, great variation in costs across upper and
lower quartile estimates based on variations in resource use
suggest that larger trials are warranted. These data mirror the
effectiveness results that had been noted and were surprising,
considering the relative safety of MRCP compared with the more
invasive (but also therapeutic) ERCP. These ﬁndings also empha-
size the need for true medical effectiveness trials measuring
clinically relevant outcomes when comparing diagnostic strat-
egies, regardless of how far downstream they may occur in the
patient clinical management pathways.
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